What Is Cytogenetic Testing and Why Is It Performed?

Cytogenetic testing is a category of laboratory analysis that examines chromosomes for abnormalities in their number, structure, or arrangement. It is performed whenever a clinician suspects that a patient’s condition, or risk of one, traces back to a problem at the chromosome level. The applications span prenatal care, cancer diagnosis, unexplained developmental delays in children, and recurrent miscarriage in couples trying to conceive. What began decades ago with simple staining of chromosomes under a microscope has expanded into a suite of techniques ranging from classical banding to high-resolution microarray platforms, each suited to different clinical questions.

What Cytogenetic Testing Actually Looks At

Your DNA is packaged into 46 chromosomes, arranged in 23 pairs. Cytogenetic testing asks whether those chromosomes are intact. The simplest problems are numerical: an extra copy of chromosome 21 causes Down syndrome, an extra chromosome 18 causes Edwards syndrome, and so on. But the field also hunts for structural problems, where a piece of one chromosome has broken off and reattached in the wrong place, gone missing entirely, or ended up fused with another chromosome. These structural rearrangements can be balanced, meaning no genetic material is actually gained or lost, just rearranged, or unbalanced, meaning the person has too much or too little of certain genes. Both types matter clinically, but in different contexts.

The molecular events that lead to these chromosomal errors are varied. During the formation of eggs and sperm, chromosomes must pair up and separate cleanly. When that process goes wrong, the resulting egg or sperm carries the wrong number of chromosomes. Maternal errors during the first division of egg formation are the single most common cause of trisomies, though chromosome-specific patterns exist. For trisomy 16, for example, virtually all cases trace to maternal first-division errors, whereas trisomy 18 more often involves second-division mistakes.¹ Structural rearrangements, meanwhile, typically arise from DNA repair gone wrong after a double-strand break or a stalled replication fork, through mechanisms such as non-allelic homologous recombination and non-homologous end-joining.²

The Core Techniques

Cytogenetic testing is not one test but a family of them, each with different strengths. The classical approach, still widely used, is G-banded karyotyping. Newer molecular methods like FISH and chromosomal microarray analysis (CMA) detect things that karyotyping cannot. Understanding which test is being ordered, and why, helps make sense of the results.

G-Banded Karyotyping

Karyotyping requires living, dividing cells. After a sample is collected, whether blood, bone marrow, amniotic fluid, or tissue, the cells are cultured and then treated with a chemical called Colcemid that freezes them at the stage of cell division when chromosomes are most condensed and visible. The cells are swollen with a salt solution, preserved with fixative, and dropped onto glass slides. To make the banding pattern visible, the chromosomes are briefly exposed to the enzyme trypsin and then stained with Giemsa dye, producing the characteristic alternating light and dark stripes that allow trained analysts to identify each chromosome and spot rearrangements.³ This entire process is manual and depends on the analyst’s experience.⁴

Karyotyping excels at providing a panoramic view of all 46 chromosomes at once. It can catch extra or missing whole chromosomes, large deletions or duplications, balanced translocations where chunks of two chromosomes have swapped places, and inversions where a segment has flipped orientation. Its main limitation is resolution: it cannot detect changes smaller than about five to ten million base pairs of DNA. That means small but clinically important deletions or duplications, known as microdeletions and microduplications, slip through undetected. It also requires cell culture, which takes time and can occasionally fail.

Fluorescence In Situ Hybridization

FISH uses fluorescently labeled DNA probes designed to stick to a specific chromosome region. Under a fluorescence microscope, you can literally see whether the target region is present, absent, or in the wrong location. FISH is fast, often returning results in a day or two rather than the one to two weeks karyotyping needs, and it does not always require cultured cells. It is the go-to test when clinicians already have a specific abnormality in mind, like checking for a known deletion syndrome or confirming that a cancer carries a particular gene fusion.⁵ The trade-off is that FISH only answers the question it is designed for. It looks at a handful of targeted spots, not the whole genome.

Chromosomal Microarray Analysis

CMA scans the entire genome at much higher resolution than a karyotype. Instead of looking at chromosomes under a microscope, it measures the amount of DNA present at hundreds of thousands of markers across the genome, detecting gains and losses too small for karyotyping to see. One widely used platform, for example, contains more than 750,000 markers for copy number analysis.⁶ CMA is automated, provides results faster than karyotyping, and removes much of the subjectivity of human interpretation.⁴ However, CMA has its own blind spots: it cannot detect balanced rearrangements, where DNA is rearranged but no material is gained or lost, and it cannot identify triploidy, a condition where every chromosome has an extra copy. A landmark study in the New England Journal of Medicine confirmed that microarray analysis caught all the unbalanced abnormalities that karyotyping caught, but missed balanced translocations and triploidy.⁷

This is why no single cytogenetic test replaces all the others. Each has a complementary strength, and the clinical question dictates which test, or combination, is ordered.

Prenatal Testing

One of the most common reasons cytogenetic testing is performed is during pregnancy, when an ultrasound finding, maternal age, or a screening result raises concern about a fetal chromosome abnormality. The two main ways to collect fetal cells for cytogenetic analysis are chorionic villus sampling (CVS), typically done between 10 and 13 weeks of pregnancy, and amniocentesis, usually performed between 15 and 20 weeks. Both are invasive, meaning they require a needle to be inserted through the abdomen.

Historically, amniocentesis has been more popular than CVS for cytogenetic analysis. Research comparing the two found that while laboratory failure rates were comparable, the quality of the banding pattern and the reliability of results in representing the true fetal karyotype were somewhat better from amniotic fluid cells, though CVS performed equally well when both short-term and long-term cultures were analyzed together.⁸

The rise of non-invasive prenatal testing (NIPT), which analyzes fragments of fetal DNA circulating in the mother’s blood, has changed how many pregnancies are screened. NIPT can flag common trisomies and sex chromosome abnormalities with high sensitivity. But NIPT is a screening test, not a diagnostic one. In roughly one in a thousand cases, the NIPT result and the actual fetal karyotype are discordant, sometimes because the abnormal DNA came from the placenta rather than the fetus itself, a phenomenon called feto-placental mosaicism.⁹ For this reason, a positive NIPT result should always be confirmed with invasive testing, preferably amniocentesis, to obtain the actual fetal karyotype.¹⁰ The confirmatory testing that follows a positive NIPT screen commonly involves FISH, karyotyping, and CMA, sometimes all three on the same sample.¹¹

CMA has become especially valuable in prenatal cases where the fetus has a structural abnormality on ultrasound, such as a congenital heart defect, but a normal karyotype. In fetuses with congenital heart disease, CMA and karyotyping together detected total abnormalities in about 22% of cases, including a roughly 6% rate of small pathogenic copy number changes that a standard karyotype alone would have missed.¹²

Cancer Diagnosis, Prognosis, and Treatment Selection

Chromosome abnormalities are not just inherited or present from birth. Cancers acquire their own set of chromosomal changes as they develop, and identifying those changes is often essential for diagnosis, predicting how aggressive the cancer will be, and choosing the right therapy. This is especially true in blood cancers, where cytogenetic testing has been embedded in standard care for decades.

The Philadelphia chromosome, a specific translocation between chromosomes 9 and 22, is a defining feature of chronic myeloid leukemia and a subset of acute lymphoblastic leukemia (ALL). Detecting it tells clinicians to use a targeted drug called a tyrosine kinase inhibitor. Researchers have also examined whether additional cytogenetic abnormalities on top of the Philadelphia chromosome worsen outcomes. In patients with Philadelphia-positive ALL who received a tyrosine kinase inhibitor followed by a stem cell transplant, the presence of additional cytogenetic abnormalities did not significantly worsen transplant outcomes, suggesting the targeted therapy may overcome the extra risk.¹³ Still, cataloging those additional abnormalities through cytogenetic testing remains important for building prediction models that factor in gene deletions and residual disease status alongside the karyotype findings.¹⁴

In solid tumors, cytogenetic methods like FISH play a different but equally important role. Structural gene rearrangements that produce fusion proteins can drive tumor growth and serve as druggable targets. Identifying these fusions aids both diagnosis and treatment selection.¹⁵ FISH probes designed to detect amplification of growth-related genes are commercially available and already used clinically; similar approaches targeting other genes involved in cell growth and differentiation are expected to expand in the future.¹⁶

Recurrent Pregnancy Loss

Couples who experience repeated miscarriages are frequently offered cytogenetic testing of their own blood. The goal is to find out whether one partner carries a balanced chromosomal rearrangement that, while causing no symptoms in the carrier, produces unbalanced chromosomes in their eggs or sperm, leading to pregnancies that cannot survive. A large cross-sectional study of over 4,000 couples with recurrent pregnancy loss in Turkey detected chromosomal abnormalities in about 3.3% of cases. The vast majority of those were structural, with reciprocal translocations accounting for roughly two-thirds and Robertsonian translocations making up another 20%.¹⁷ A separate analysis of more than 16,000 couples found a similar rate, roughly one in 35 couples carrying a balanced translocation or inversion.¹⁸

Finding a balanced rearrangement does not mean the couple cannot have healthy children. It means their pregnancies carry an elevated risk of chromosomal imbalance, and it opens the door to options like preimplantation genetic testing during IVF, where embryos can be screened for the specific imbalance before transfer. Without cytogenetic testing, these couples might endure multiple additional losses before the underlying cause is identified.

Developmental Delay, Intellectual Disability, and Autism

Cytogenetic testing is also a front-line investigation when a child presents with unexplained developmental delay, intellectual disability, autism spectrum disorder, or multiple birth defects. Chromosomal microarray analysis has been endorsed as the first-tier genetic test for these children, because it can identify submicroscopic deletions and duplications that would escape detection by a standard karyotype.¹⁹ A study from Hong Kong reinforced this recommendation, finding that CMA is especially valuable for children with severe disease.²⁰

Receiving a chromosomal diagnosis can be genuinely life-changing for families who have spent years searching for answers. It can connect them to condition-specific support groups, inform expectations about the child’s development, alert clinicians to associated medical complications that need monitoring, and, in some cases, guide reproductive decisions for future pregnancies.

The Mosaicism Problem

One complexity that runs through nearly every application of cytogenetic testing is mosaicism, the presence of two or more cell populations with different chromosome constitutions in the same individual. Mosaicism can arise when a chromosome error occurs not during egg or sperm formation but after fertilization, during the early divisions of the embryo. The clinical impact depends on several factors: how large the abnormality is, when in development the error occurred, which tissues ended up with the abnormal cells, and what proportion of cells in those tissues are affected.²¹

Mosaicism complicates testing because the sample you analyze might not reflect what is going on in the rest of the body. A blood draw might show a normal karyotype while the affected tissue carries an abnormal one. In prenatal testing, the placenta and the fetus can have different chromosome profiles, which is precisely why NIPT sometimes gives a result that does not match the fetus. Laboratories follow rules about how many cells must be analyzed to confidently detect or rule out mosaicism, but low-level mosaicism can still be missed.

Variants of Uncertain Significance

As cytogenetic testing has become more powerful, particularly with the shift toward genome-wide microarray analysis, a new clinical challenge has emerged: finding things whose meaning is unclear. High-resolution platforms can detect tiny duplications or deletions that have never been described before in medical literature. Are they causing the patient’s symptoms, or are they harmless variants? These so-called variants of uncertain significance (VUS) create real anxiety for patients and difficult conversations for genetic counselors.²²

In the prenatal setting, this tension is particularly acute. A pregnant person who undergoes CMA hoping for reassurance might instead receive an ambiguous result that cannot be fully interpreted until more data accumulate, sometimes years later. Genetic counseling before testing is important precisely because patients need to understand that higher-resolution testing can deliver this kind of uncertain news alongside its clear benefits.

Optical Genome Mapping and the Next Generation of Testing

The current standard for a comprehensive cytogenetic workup, especially in blood cancers, often requires running karyotyping, FISH, and CMA in parallel. Each test catches things the others miss, but using all three is expensive, time-consuming, and requires significant laboratory expertise. A newer technology called optical genome mapping (OGM) aims to consolidate these tests into a single assay. OGM works by labeling and imaging ultra-long DNA molecules, allowing it to detect both structural rearrangements and copy number changes across the genome in one run.

Studies evaluating OGM in blood cancers have found it highly concordant with the standard combination of cytogenetic techniques, achieving perfect sensitivity and a positive predictive value above 80% in one assessment of 52 blood cancer genomes.²³ Beyond matching existing tests, OGM has also revealed previously undetected structural variants that were clinically significant, improving patient classification and treatment decisions.²⁴ The technology is still transitioning from research into routine clinical use, but it represents a plausible near-term future in which a single platform handles what currently takes three separate tests and three separate workflows.

When a Normal Result Does Not Mean Nothing Is Wrong

A common misconception is that a normal cytogenetic test rules out a genetic cause for a condition. It does not. Cytogenetic testing, even at its most advanced, only detects abnormalities above a certain size threshold, and it focuses on chromosomal-level changes. Many genetic conditions are caused by mutations within a single gene, which are too small to be caught by any cytogenetic method. A child with an unexplained developmental delay might have a normal karyotype and a normal microarray but still carry a single-gene mutation detectable only by exome or genome sequencing. Similarly, a couple with recurrent miscarriage might have normal karyotypes but carry other genetic variants affecting embryo viability.

The field has evolved from classical Giemsa staining to three-dimensional spatial mapping of chromosomes with nucleotide-level resolution.²⁵ Yet each advance expands the gray zone alongside the clarity. More resolution means more findings, and more findings means more complexity in interpretation. The practical takeaway for anyone undergoing cytogenetic testing is to expect a conversation, not just a result. Genetic counseling should precede and follow the test, especially when the higher-resolution platforms are involved, because the results may answer one question while opening another.